This stands in contrast to the successes realized in developing small molecule protein kinase inhibitors to treat a number of other malignancies, including melanomas, renal cell carcinoma, chronic myelogenous leukemia, and cancers of the lung and thyroid. This evidence concerns the gene WEE1 and chronic myelogenous leukemia, BCR-ABL1 positive.